Review



tissue microarray data of runx1 in breast cancer patients  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Human Protein Atlas tissue microarray data of runx1 in breast cancer patients
    (A) Representative tissue microarray images of <t>RUNX1</t> in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.
    Tissue Microarray Data Of Runx1 In Breast Cancer Patients, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray data of runx1 in breast cancer patients/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    tissue microarray data of runx1 in breast cancer patients - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor"

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    Journal: Molecular cancer research : MCR

    doi: 10.1158/1541-7786.MCR-18-0135

    (A) Representative tissue microarray images of RUNX1 in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.
    Figure Legend Snippet: (A) Representative tissue microarray images of RUNX1 in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.

    Techniques Used: Microarray, Expressing

    (A) MCF10CA1a cells were injected into the mammary fat pad of SCID mice. Points represent mean tumor volume. (B) Western blot analyses show RUNX1 and E-cadherin levels are decreased, and Vimentin level is increased in tumor samples compared to MCF10CA1a cells. (C) Protein quantification show that RUNX1 is significant decreased in tumor samples compared to MCF10CA1a cells (Upper). RT-qPCR analyses of RNA from tumor samples show decreased human RUNX1 expression of compared with MCF10CA1a cells. Mouse embryonic fibroblast (MEF) is used as the negative control as human Runx1 is not detected in those samples (Lower). Student’s t test * p value <0.05, *** p value <0.001 and. Error bars represent the standard error of the mean (SEM) from three independent experiments. (D) RT-qPCR analyses of RNA from tumor samples show activation of mesenchymal marks Vimentin and FN1 and other tumor growth related genes including MMP9, MMP13, VGF, CXCR4 and CXCL12 compared with MCF10CA1a cells. The primers of these genes are human specific as they are tested negative in mouse embryonic fibroblast. Student’s t test * p value <0.05, ** p value <0.01, *** p value <0.001 and **** p value <0.0001. Error bars represent the standard error of the mean (SEM) from three independent experiments.
    Figure Legend Snippet: (A) MCF10CA1a cells were injected into the mammary fat pad of SCID mice. Points represent mean tumor volume. (B) Western blot analyses show RUNX1 and E-cadherin levels are decreased, and Vimentin level is increased in tumor samples compared to MCF10CA1a cells. (C) Protein quantification show that RUNX1 is significant decreased in tumor samples compared to MCF10CA1a cells (Upper). RT-qPCR analyses of RNA from tumor samples show decreased human RUNX1 expression of compared with MCF10CA1a cells. Mouse embryonic fibroblast (MEF) is used as the negative control as human Runx1 is not detected in those samples (Lower). Student’s t test * p value <0.05, *** p value <0.001 and. Error bars represent the standard error of the mean (SEM) from three independent experiments. (D) RT-qPCR analyses of RNA from tumor samples show activation of mesenchymal marks Vimentin and FN1 and other tumor growth related genes including MMP9, MMP13, VGF, CXCR4 and CXCL12 compared with MCF10CA1a cells. The primers of these genes are human specific as they are tested negative in mouse embryonic fibroblast. Student’s t test * p value <0.05, ** p value <0.01, *** p value <0.001 and **** p value <0.0001. Error bars represent the standard error of the mean (SEM) from three independent experiments.

    Techniques Used: Injection, Western Blot, Quantitative RT-PCR, Expressing, Negative Control, Activation Assay

    (A) Western blot analyses confirm RUNX1 overexpression in MCF10AT1 (Upper) and MCF10CA1a (Lower) cells. Vimentin expression is repressed upon RUNX1 overexpression in both cell lines. (B) Representative phase contrast images (magnification 100×) of MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression subjected to a scratch assay for times indicated. The area of the scratch was plotted as a percentage of total area for N = 3 independent experiments carried out in duplicate. (C) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N = 2) trans-well migration assay experiment MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression (left); quantitation of migrated cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by migrated cells (right). (D) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N= 2) trans-well matrigel invasion assay experiment with MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression to evaluate invasion (left); quantitation of invaded cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by invaded cells (right). For all assays, three independent experiments were carried out in duplicates. All quantitative data are depicted as mean ± S.E. per group. *P < 0.05, **P < 0.01 (student’s t-test).
    Figure Legend Snippet: (A) Western blot analyses confirm RUNX1 overexpression in MCF10AT1 (Upper) and MCF10CA1a (Lower) cells. Vimentin expression is repressed upon RUNX1 overexpression in both cell lines. (B) Representative phase contrast images (magnification 100×) of MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression subjected to a scratch assay for times indicated. The area of the scratch was plotted as a percentage of total area for N = 3 independent experiments carried out in duplicate. (C) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N = 2) trans-well migration assay experiment MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression (left); quantitation of migrated cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by migrated cells (right). (D) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N= 2) trans-well matrigel invasion assay experiment with MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression to evaluate invasion (left); quantitation of invaded cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by invaded cells (right). For all assays, three independent experiments were carried out in duplicates. All quantitative data are depicted as mean ± S.E. per group. *P < 0.05, **P < 0.01 (student’s t-test).

    Techniques Used: Western Blot, Over Expression, Expressing, Control, Wound Healing Assay, Light Microscopy, Staining, Migration, Quantitation Assay, Invasion Assay

    (A) A total of 1 × 106 MCF10CA1a cells with EV or RUNX1 overexpression were injected into mammary fat pad of SCID mice (n = 7 in each group). The points represent average tumor volume at each time point ± SD. P values were obtained by 2-tailed Student t test. *, P < 0.05; ***, P<0.001; ****, P<0.0001. (B) Tumor size measured at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (C) Tumor weight at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (D) Representative luminescence images at 4 weeks after mammary fat pad injection.
    Figure Legend Snippet: (A) A total of 1 × 106 MCF10CA1a cells with EV or RUNX1 overexpression were injected into mammary fat pad of SCID mice (n = 7 in each group). The points represent average tumor volume at each time point ± SD. P values were obtained by 2-tailed Student t test. *, P < 0.05; ***, P<0.001; ****, P<0.0001. (B) Tumor size measured at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (C) Tumor weight at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (D) Representative luminescence images at 4 weeks after mammary fat pad injection.

    Techniques Used: Over Expression, Injection

    (A) Western blot analyses show RUNX1 is decreased and Zeb1, Twist1 and Vimentin level are increased in BCSC samples compared to Parental and Bulk MCF10AT1 cells. Right, protein quantification shows that RUNX1 is significant decreased in BCSC. (B) Tumorsphere formation efficiency for BCSC populations is significantly higher than bulk population. **P < 0.01. (C) RUNX1 overexpression in MCF10CA1a cells reduces tumorsphere formation efficiency. *P < 0.05. Right, represent picture of tumorsphere. (D) RUNX1 overexpression in MCF10AT1 cells reduces tumorsphere formation efficiency. *P < 0.05 Right, represent picture of tumorsphere. (E) Western blot analyses of lysates from MCF10AT1 cells treated with shRUNX1 show decreased protein expression of RUNX1 and E-cadherin and increased protein expression of Vimentin. (F) RUNX1 knockdown in MCF10AT1 cells activates tumorsphere formation efficiency. *P < 0.05. Right, represents picture of tumorsphere.
    Figure Legend Snippet: (A) Western blot analyses show RUNX1 is decreased and Zeb1, Twist1 and Vimentin level are increased in BCSC samples compared to Parental and Bulk MCF10AT1 cells. Right, protein quantification shows that RUNX1 is significant decreased in BCSC. (B) Tumorsphere formation efficiency for BCSC populations is significantly higher than bulk population. **P < 0.01. (C) RUNX1 overexpression in MCF10CA1a cells reduces tumorsphere formation efficiency. *P < 0.05. Right, represent picture of tumorsphere. (D) RUNX1 overexpression in MCF10AT1 cells reduces tumorsphere formation efficiency. *P < 0.05 Right, represent picture of tumorsphere. (E) Western blot analyses of lysates from MCF10AT1 cells treated with shRUNX1 show decreased protein expression of RUNX1 and E-cadherin and increased protein expression of Vimentin. (F) RUNX1 knockdown in MCF10AT1 cells activates tumorsphere formation efficiency. *P < 0.05. Right, represents picture of tumorsphere.

    Techniques Used: Western Blot, Over Expression, Expressing, Knockdown

    (A) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells with EV or RUNX1 overexpression. (B) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells stably expressing RUNX1 or non-silencing shRNAs.
    Figure Legend Snippet: (A) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells with EV or RUNX1 overexpression. (B) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells stably expressing RUNX1 or non-silencing shRNAs.

    Techniques Used: Expressing, Over Expression, Stable Transfection

    (A) Western blot analyses show Zeb1 is decreased upon RUNX1 overexpression in MCF10AT1 cells. (B) Western blot analyses show Zeb1 is activated upon RUNX1 knockdown in MCF10AT1 cells. (C) ChIP-qPCR confirmation of RUNX1 occupancy at Zeb1. RUNX1 binding is increased in RUNX1 overexpression samples. Data obtained with antibodies against RUNX1 are normalized to input control and ZNF188 (NC1) and ZNF333 (NC2), which were used as the negative control as RUNX1 are predicted not to bind these genes. (D) Western blot analyses show Zeb1 knockdown by siRNA in MCF10AT1 RUNX1 depleted cells. (E) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells RUNX1 and Zeb1 double knockdown cells. *P<0.05 (F) Zeb1 knockdown in MCF10AT1 RUNX1 depleted cells reduces tumorsphere formation efficiency. ***P < 0.001 (G) Mechanism on how RUNX1 represses tumor growth in breast cancer. (EC-epithelial like cells; MC-mesenchymal-like cells).
    Figure Legend Snippet: (A) Western blot analyses show Zeb1 is decreased upon RUNX1 overexpression in MCF10AT1 cells. (B) Western blot analyses show Zeb1 is activated upon RUNX1 knockdown in MCF10AT1 cells. (C) ChIP-qPCR confirmation of RUNX1 occupancy at Zeb1. RUNX1 binding is increased in RUNX1 overexpression samples. Data obtained with antibodies against RUNX1 are normalized to input control and ZNF188 (NC1) and ZNF333 (NC2), which were used as the negative control as RUNX1 are predicted not to bind these genes. (D) Western blot analyses show Zeb1 knockdown by siRNA in MCF10AT1 RUNX1 depleted cells. (E) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells RUNX1 and Zeb1 double knockdown cells. *P<0.05 (F) Zeb1 knockdown in MCF10AT1 RUNX1 depleted cells reduces tumorsphere formation efficiency. ***P < 0.001 (G) Mechanism on how RUNX1 represses tumor growth in breast cancer. (EC-epithelial like cells; MC-mesenchymal-like cells).

    Techniques Used: Western Blot, Over Expression, Knockdown, ChIP-qPCR, Binding Assay, Control, Negative Control, Expressing



    Similar Products

    tissue microarray data of runx1 in breast cancer patients  (Human Protein Atlas)
    90
    Human Protein Atlas tissue microarray data of runx1 in breast cancer patients
    (A) Representative tissue microarray images of <t>RUNX1</t> in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.
    Tissue Microarray Data Of Runx1 In Breast Cancer Patients, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray data of runx1 in breast cancer patients/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    tissue microarray data of runx1 in breast cancer patients - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Representative tissue microarray images of RUNX1 in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) Representative tissue microarray images of RUNX1 in normal breast tissue. (B) and (C) Representative tissue microarray images of RUNX1 in breast tumor tissues. Red circle: malignant regions; Blue circle: normal glandular tissues. (D) Kaplan-Meier analysis showed higher overall survival in patients with higher RUNX1 mRNA expression (GSE37751, GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, p value<0.05, p value<0.01 respectively, comparing patients with high RUNX1 expression and low RUNX1 expression in three data sets.

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Microarray, Expressing

    (A) MCF10CA1a cells were injected into the mammary fat pad of SCID mice. Points represent mean tumor volume. (B) Western blot analyses show RUNX1 and E-cadherin levels are decreased, and Vimentin level is increased in tumor samples compared to MCF10CA1a cells. (C) Protein quantification show that RUNX1 is significant decreased in tumor samples compared to MCF10CA1a cells (Upper). RT-qPCR analyses of RNA from tumor samples show decreased human RUNX1 expression of compared with MCF10CA1a cells. Mouse embryonic fibroblast (MEF) is used as the negative control as human Runx1 is not detected in those samples (Lower). Student’s t test * p value <0.05, *** p value <0.001 and. Error bars represent the standard error of the mean (SEM) from three independent experiments. (D) RT-qPCR analyses of RNA from tumor samples show activation of mesenchymal marks Vimentin and FN1 and other tumor growth related genes including MMP9, MMP13, VGF, CXCR4 and CXCL12 compared with MCF10CA1a cells. The primers of these genes are human specific as they are tested negative in mouse embryonic fibroblast. Student’s t test * p value <0.05, ** p value <0.01, *** p value <0.001 and **** p value <0.0001. Error bars represent the standard error of the mean (SEM) from three independent experiments.

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) MCF10CA1a cells were injected into the mammary fat pad of SCID mice. Points represent mean tumor volume. (B) Western blot analyses show RUNX1 and E-cadherin levels are decreased, and Vimentin level is increased in tumor samples compared to MCF10CA1a cells. (C) Protein quantification show that RUNX1 is significant decreased in tumor samples compared to MCF10CA1a cells (Upper). RT-qPCR analyses of RNA from tumor samples show decreased human RUNX1 expression of compared with MCF10CA1a cells. Mouse embryonic fibroblast (MEF) is used as the negative control as human Runx1 is not detected in those samples (Lower). Student’s t test * p value <0.05, *** p value <0.001 and. Error bars represent the standard error of the mean (SEM) from three independent experiments. (D) RT-qPCR analyses of RNA from tumor samples show activation of mesenchymal marks Vimentin and FN1 and other tumor growth related genes including MMP9, MMP13, VGF, CXCR4 and CXCL12 compared with MCF10CA1a cells. The primers of these genes are human specific as they are tested negative in mouse embryonic fibroblast. Student’s t test * p value <0.05, ** p value <0.01, *** p value <0.001 and **** p value <0.0001. Error bars represent the standard error of the mean (SEM) from three independent experiments.

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Injection, Western Blot, Quantitative RT-PCR, Expressing, Negative Control, Activation Assay

    (A) Western blot analyses confirm RUNX1 overexpression in MCF10AT1 (Upper) and MCF10CA1a (Lower) cells. Vimentin expression is repressed upon RUNX1 overexpression in both cell lines. (B) Representative phase contrast images (magnification 100×) of MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression subjected to a scratch assay for times indicated. The area of the scratch was plotted as a percentage of total area for N = 3 independent experiments carried out in duplicate. (C) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N = 2) trans-well migration assay experiment MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression (left); quantitation of migrated cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by migrated cells (right). (D) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N= 2) trans-well matrigel invasion assay experiment with MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression to evaluate invasion (left); quantitation of invaded cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by invaded cells (right). For all assays, three independent experiments were carried out in duplicates. All quantitative data are depicted as mean ± S.E. per group. *P < 0.05, **P < 0.01 (student’s t-test).

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) Western blot analyses confirm RUNX1 overexpression in MCF10AT1 (Upper) and MCF10CA1a (Lower) cells. Vimentin expression is repressed upon RUNX1 overexpression in both cell lines. (B) Representative phase contrast images (magnification 100×) of MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression subjected to a scratch assay for times indicated. The area of the scratch was plotted as a percentage of total area for N = 3 independent experiments carried out in duplicate. (C) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N = 2) trans-well migration assay experiment MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression (left); quantitation of migrated cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by migrated cells (right). (D) Light microscopy images (mag. 12×) of stained cells from a representative (1 of N= 2) trans-well matrigel invasion assay experiment with MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 overexpression to evaluate invasion (left); quantitation of invaded cells assessed by measurement of the absorbance of solubilized crystal violet stain retained by invaded cells (right). For all assays, three independent experiments were carried out in duplicates. All quantitative data are depicted as mean ± S.E. per group. *P < 0.05, **P < 0.01 (student’s t-test).

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Western Blot, Over Expression, Expressing, Control, Wound Healing Assay, Light Microscopy, Staining, Migration, Quantitation Assay, Invasion Assay

    (A) A total of 1 × 106 MCF10CA1a cells with EV or RUNX1 overexpression were injected into mammary fat pad of SCID mice (n = 7 in each group). The points represent average tumor volume at each time point ± SD. P values were obtained by 2-tailed Student t test. *, P < 0.05; ***, P<0.001; ****, P<0.0001. (B) Tumor size measured at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (C) Tumor weight at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (D) Representative luminescence images at 4 weeks after mammary fat pad injection.

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) A total of 1 × 106 MCF10CA1a cells with EV or RUNX1 overexpression were injected into mammary fat pad of SCID mice (n = 7 in each group). The points represent average tumor volume at each time point ± SD. P values were obtained by 2-tailed Student t test. *, P < 0.05; ***, P<0.001; ****, P<0.0001. (B) Tumor size measured at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (C) Tumor weight at day 28 (end point). P values were obtained by 2-tailed Student t test. *, P < 0.05. (D) Representative luminescence images at 4 weeks after mammary fat pad injection.

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Over Expression, Injection

    (A) Western blot analyses show RUNX1 is decreased and Zeb1, Twist1 and Vimentin level are increased in BCSC samples compared to Parental and Bulk MCF10AT1 cells. Right, protein quantification shows that RUNX1 is significant decreased in BCSC. (B) Tumorsphere formation efficiency for BCSC populations is significantly higher than bulk population. **P < 0.01. (C) RUNX1 overexpression in MCF10CA1a cells reduces tumorsphere formation efficiency. *P < 0.05. Right, represent picture of tumorsphere. (D) RUNX1 overexpression in MCF10AT1 cells reduces tumorsphere formation efficiency. *P < 0.05 Right, represent picture of tumorsphere. (E) Western blot analyses of lysates from MCF10AT1 cells treated with shRUNX1 show decreased protein expression of RUNX1 and E-cadherin and increased protein expression of Vimentin. (F) RUNX1 knockdown in MCF10AT1 cells activates tumorsphere formation efficiency. *P < 0.05. Right, represents picture of tumorsphere.

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) Western blot analyses show RUNX1 is decreased and Zeb1, Twist1 and Vimentin level are increased in BCSC samples compared to Parental and Bulk MCF10AT1 cells. Right, protein quantification shows that RUNX1 is significant decreased in BCSC. (B) Tumorsphere formation efficiency for BCSC populations is significantly higher than bulk population. **P < 0.01. (C) RUNX1 overexpression in MCF10CA1a cells reduces tumorsphere formation efficiency. *P < 0.05. Right, represent picture of tumorsphere. (D) RUNX1 overexpression in MCF10AT1 cells reduces tumorsphere formation efficiency. *P < 0.05 Right, represent picture of tumorsphere. (E) Western blot analyses of lysates from MCF10AT1 cells treated with shRUNX1 show decreased protein expression of RUNX1 and E-cadherin and increased protein expression of Vimentin. (F) RUNX1 knockdown in MCF10AT1 cells activates tumorsphere formation efficiency. *P < 0.05. Right, represents picture of tumorsphere.

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Western Blot, Over Expression, Expressing, Knockdown

    (A) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells with EV or RUNX1 overexpression. (B) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells stably expressing RUNX1 or non-silencing shRNAs.

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells with EV or RUNX1 overexpression. (B) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells stably expressing RUNX1 or non-silencing shRNAs.

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Expressing, Over Expression, Stable Transfection

    (A) Western blot analyses show Zeb1 is decreased upon RUNX1 overexpression in MCF10AT1 cells. (B) Western blot analyses show Zeb1 is activated upon RUNX1 knockdown in MCF10AT1 cells. (C) ChIP-qPCR confirmation of RUNX1 occupancy at Zeb1. RUNX1 binding is increased in RUNX1 overexpression samples. Data obtained with antibodies against RUNX1 are normalized to input control and ZNF188 (NC1) and ZNF333 (NC2), which were used as the negative control as RUNX1 are predicted not to bind these genes. (D) Western blot analyses show Zeb1 knockdown by siRNA in MCF10AT1 RUNX1 depleted cells. (E) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells RUNX1 and Zeb1 double knockdown cells. *P<0.05 (F) Zeb1 knockdown in MCF10AT1 RUNX1 depleted cells reduces tumorsphere formation efficiency. ***P < 0.001 (G) Mechanism on how RUNX1 represses tumor growth in breast cancer. (EC-epithelial like cells; MC-mesenchymal-like cells).

    Journal: Molecular cancer research : MCR

    Article Title: Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor

    doi: 10.1158/1541-7786.MCR-18-0135

    Figure Lengend Snippet: (A) Western blot analyses show Zeb1 is decreased upon RUNX1 overexpression in MCF10AT1 cells. (B) Western blot analyses show Zeb1 is activated upon RUNX1 knockdown in MCF10AT1 cells. (C) ChIP-qPCR confirmation of RUNX1 occupancy at Zeb1. RUNX1 binding is increased in RUNX1 overexpression samples. Data obtained with antibodies against RUNX1 are normalized to input control and ZNF188 (NC1) and ZNF333 (NC2), which were used as the negative control as RUNX1 are predicted not to bind these genes. (D) Western blot analyses show Zeb1 knockdown by siRNA in MCF10AT1 RUNX1 depleted cells. (E) Flow cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells RUNX1 and Zeb1 double knockdown cells. *P<0.05 (F) Zeb1 knockdown in MCF10AT1 RUNX1 depleted cells reduces tumorsphere formation efficiency. ***P < 0.001 (G) Mechanism on how RUNX1 represses tumor growth in breast cancer. (EC-epithelial like cells; MC-mesenchymal-like cells).

    Article Snippet: Tissue microarray data of RUNX1 in breast cancer patients were obtained from Human Protein Atlas ( www.proteinatlas.org ) [ 40 ].

    Techniques: Western Blot, Over Expression, Knockdown, ChIP-qPCR, Binding Assay, Control, Negative Control, Expressing